Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trialDan Liu, Lin Shen, Haiping Jiang et al.|BMC Medicine|2022Cited by 84
Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysisMingjun Li, Mingzhi Zhang|International Journal of Molecular Medicine|2015Cited by 34